News Search Results
Mar 28, 2026, 12:36 ET Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting
March 28, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today showcased data in two presentations at the 2026 American Academy of Dermatology (AAD) Annual Meeting taking place in Denver, CO.
More news about: Nektar Therapeutics
Mar 28, 2026, 10:00 ET ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis
first and only targeted oral peptide that precisely blocks the IL-23 receptor.1 These data are being presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting.
More news about: Johnson & Johnson
Mar 27, 2026, 10:44 ET Sun Pharma Highlights Advances in Alopecia Areata, Psoriasis, and Acne Research at 2026 AAD Annual Meeting
with its subsidiaries and/or affiliated companies, "Sun Pharma") today announced the company will present 14 abstracts during the 2026 American Academy of Dermatology (AAD) Annual Meeting on March 27-31, 2026 in Denver, Colorado. The breadth of data reinforces the company's expertise across dermatology
More news about: Sun Pharma
Mar 27, 2026, 10:00 ET AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting
2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new research across its dermatology portfolio to be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, March 27–31 in Denver, Colorado. AbbVie will present 24 abstracts at AAD, including one late-breaking presentation,
More news about: AbbVie
Mar 27, 2026, 09:05 ET Castle Biosciences' DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026
Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will present new data at the 2026 American Academy of Dermatology (AAD) Annual Meeting, taking place March 27–31 in Denver, demonstrating that its DecisionDx-Melanoma test refines mortality risk within
More news about: Castle Biosciences, Inc.
Mar 27, 2026, 09:03 ET OLAY Unveils Proprietary Research on Cell Adhesion as a Key Driver of Skin Aging at AAD 2026
OLAY, the #1 anti-aging skin care brand with more than 70 years of skin science expertise, is announcing new research at the 2026 American Academy of Dermatology (AAD) Annual Meeting, identifying cell adhesion as a critical biological driver of visible skin aging. These findings provide new insight
More news about: OLAY
Mar 27, 2026, 09:00 ET Murad Alam, MD, MSCI, MBA, FAAD, assumes presidency of the American Academy of Dermatology
/PRNewswire/ -- Chicago-based board-certified dermatologist Murad Alam, MD, MSCI, MBA, FAAD, will begin his one-year term as president of the American Academy of Dermatology at the close of the AAD's Annual Meeting.
More news about: American Academy of Dermatology
Mar 27, 2026, 09:00 ET American Academy of Dermatology Installs New Officers, Board Members
2026 /PRNewswire/ -- Two new officers and four new board members will be installed upon the conclusion of the 2026 Annual Meeting of the American Academy of Dermatology. The officers and board members are all board-certified dermatologists and members of the AAD, the world's largest dermatologic society
More news about: American Academy of Dermatology
Mar 27, 2026, 09:00 ET The future of skin aging may be found in the kitchen: 2026 American Academy of Dermatology Annual Meeting to highlight latest advancements in skin, hair, and nails
Emerging research on the role of nutrition in skin aging is one of the timely and impactful topics that will be discussed at the 2026 American Academy of Dermatology (AAD) Annual Meeting, held March 27-31 in Denver, Colorado.
More news about: American Academy of Dermatology
Mar 27, 2026, 09:00 ET Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis
offering once-monthly maintenance injection. Interim findings from the first year of the ADlong Phase 3b study will be presented at the American Academy of Dermatology (AAD) Annual Meeting, taking place March 27-31 in Denver.1 "These data underscore our unwavering commitment to expanding
More news about: Eli Lilly and Company
Mar 27, 2026, 09:00 ET UCB Presents New BIMZELX® (bimekizumab-bkzx) Data at AAD Demonstrating High Rates of Durable and Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis
/PRNewswire/ -- UCB, a global biopharmaceutical company, today announced new data in moderate-to-severe plaque psoriasis (PSO) at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, March 27–31. These data assess BIMZELX® (bimekizumab-bkzx) in providing on-treatment remission,
More news about: UCB
Mar 27, 2026, 09:00 ET UCB Announces New BIMZELX® (bimekizumab-bkzx) Data at AAD Showing Durable Symptom Control Throughout Three Years in Hidradenitis Suppurativa
global biopharmaceutical company, today announced data for BIMZELX in active moderate-to-severe hidradenitis suppurativa (HS) at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, on March 27–31. These data from three post hoc analyses of the BE HEARD trials show the potential of BIMZELX
More news about: UCB
Mar 27, 2026, 06:45 ET Neutrogena®, Aveeno® and Rogaine® Release New Dermatology Research and Clinical Skincare Innovations on Healthy Aging, Moisturization, Sun Protection and Acne
scientific advances in UV absorption technologies, lasting hydration, barrier supporting ingredients, and preferred acne solutions at the 2026 American Academy of Dermatology Annual Meeting (AAD 2026)SUMMIT, N.J., March 27, 2026
More news about: Kenvue Inc.
Mar 26, 2026, 08:27 ET DermTech 2.0 Further Expands DermTech Stratum with Clinical Trial Support Services
www.dermtechstratum.com or talk to the DermTech Stratum team at the upcoming American Academy of Dermatology meeting in Denver, CO.
More news about: DermTech LLC
Mar 25, 2026, 09:02 ET Revance Presents Award-Winning Aesthetics and Skincare Portfolio at 2026 AAD Annual Meeting
regenerative and consumer skincare company, will showcase the latest innovations and new indications across its extensive portfolio at the American Academy of Dermatology (AAD) Annual Meeting, taking place March 27–31, 2026, in Denver, Colorado. The company will host a series of in-booth educational sessions
More news about: Revance
Mar 25, 2026, 06:03 ET New Clinical Frontiers for Acclaro's UltraClear® 2910 nm Fiber Laser Revealed by Leading Experts at the American Academy of Dermatology Annual Meeting
Fiber Focus Sessions" at the American Academy of Dermatology annual meeting on March 26-31, 2026, taking place in Denver, CO.
More news about: Acclaro Corporation
Mar 24, 2026, 09:03 ET Xtressé™ Announces FDA IND Acceptance for Xvie, The First & Only Extracellular Vesicle Injectable Therapy for Androgenetic Alopecia
application will be evaluated through the FDA clinical trial process and is not approved for use.References1American Academy of Dermatology 2024, accessed
More news about: Xtressé™
Mar 24, 2026, 07:30 ET Alphyn Completes Enrollment in Phase 2 Trial of Topical Therapy for Molluscum Contagiosum
with only one mechanism of action, directly addressing only one disease symptom.Alphyn will be exhibiting at Booth 2555 at the American Academy of Dermatology annual meeting March 27-29 in Denver. Please visit us to learn more about our platform and dermatology programs.ABOUT ALPHYN
More news about: Alphyn Biologics
Mar 23, 2026, 07:30 ET HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026
lymphoma (CTCL) are being presented at the United States Cutaneous Lymphoma Consortium (USCLC) Workshop (March 26, 2026), which precedes the American Academy of Dermatology (AAD) Annual Meeting. Ellen Kim, MD, Director, Penn Cutaneous Lymphoma Program, Vice Chair of Clinical Operations, Dermatology Department,
More news about: Soligenix
Mar 20, 2026, 10:00 ET Data from Phase 2b Studies for Rezpegaldesleukin Accepted for Two Oral Presentations at the 2026 American Academy of Dermatology Annual Meeting
Phase 2b studies of rezpegaldesleukin in atopic dermatitis and alopecia areata have been accepted for two oral presentations at the 2026 American Academy of Dermatology (AAD) Annual Meeting taking place March 27-31, 2026, in Denver, CO.
More news about: Nektar Therapeutics
Mar 18, 2026, 07:49 ET FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide
consensus on defining failure of topical therapy in psoriasis: Recommendations from the International Psoriasis Council. Journal of the American Academy of Dermatology, Volume 94, Issue 1, 372 – 375.7 Simpson E, Bissonnette R, Eichenfield LF, et al. The validated Investigator Global
More news about: Johnson & Johnson
Mar 12, 2026, 16:15 ET Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
period of the REZOLVE-AA study in patients with alopecia areata were accepted for a presentation in a late-breaking oral session at the American Academy of Dermatology (AAD) 2026 Annual Meeting to be held March 27-31, 2026, in Denver, CO.Topline data to be reported from the blinded 16-week treatment
More news about: Nektar Therapeutics
Feb 27, 2026, 08:11 ET Lilly's Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata
Psychosocial and psychiatric comorbidities and health-related quality of life in alopecia areata: A systematic review. Journal of the American Academy of Dermatology, 85(1), 162–175.
More news about: Eli Lilly and Company
Feb 24, 2026, 16:15 ET HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND INCREASES
meaningful reductions in pain and itchingZero dose-limiting toxicities observed across the entire trial to dateAt the American Academy of Dermatology Annual Meeting, a case study demonstrated complete lesion and symptom resolution after just one week of twice-daily application in a metastatic
More news about: Hoth Therapeutics, Inc.
Feb 19, 2026, 08:14 ET SciBase's Nevisense (EIS) Included in the US NCCN Guidelines for Melanoma which supports the use of EIS in the detection of melanoma
judgment," said Dr. Darrell Rigel, MD, Clinical Professor of Dermatology at the New York University (NYU), and Past President of the American Academy of Dermatology. "While visual assessment and dermoscopy have long been shown to improve melanoma detection rates, our published clinical research demonstrates
More news about: SciBase